O’HAND MS (WA40404)

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis

This study will begin recruiting participants soon.

Primary Objective: This study will evaluate the efficacy and safety of ocrelizumab compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression.

Principal Investigator: Dr Jennifer Taylor

Study Coordinator: Bri Boljonis

Trial Website: https://clinicaltrials.gov/ct2/show/NCT04035005

 

STOP-MSU

Stopping Haemorrhage with Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

This study is currently recruiting participants.

Primary Objective: This is a phase II randomised, placebo-controlled, investigator-driven trial of tranexamic acid within 2 hours of intracerebral haemorrhage. The study has 2 arms with 1:1 randomisation to either intravenous Tranexamic acid or placebo and will test the hypothesis that ICH (intracranial haemorrhage) patients treated with intravenous tranexamic acid within 2 hours of symptom onset will have lower rates of haematoma growth than compared to placebo.

Principal Investigator: Anna Ranta

Study Coordinator: Bri Boljonis

Trial Website: https://clinicaltrials.gov/ct2/show/NCT03385928

 

TASTE

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial

This study is not yet recruiting participants.

Primary Objective: The aim of this study is to test the hypothesis that patients who have experienced an acute hemispheric ischaemic stroke who have a penumbra on perfusion CT or MRI within 4.5 hours of symptom onset will have less disability at 3 months when treated with intravenous Tenecteplase (IV TNK) compared to intravenous Alteplase(IV tPA). This is a Phase III Multicentre, prospective, randomised open label blinded endpoint (PROBE) study.

Principal Investigator: Anna Ranta

Study Coordinator: Bri Boljonis

Trial Website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000243718


 

Last updated 25 November 2019.